You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The new funds will be used, in part, to support ChromaCode's expansion into resource-limited communities in low- to middle-income nations.
The first version of the platform, which the company submitted for Emergency Use Authorization to the US FDA last week, analyzes RNA extracted from a swab.
The cancer test developer will use the funding to commercialize its enrichment-based NGS panels. An IVD test also got CE marked.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
The UK-based firm anticipates that it will have a high sensitivity test available in a few months that can detect active infections.
The deals are with institutional investors and more than 1 million American Depositary Shares will be offered at A$1.75 per ADS.
The firm plans to use the cash to support commercial expansion of its NIPT to all US states and fund R&D for future diagnostic tests, including liquid biopsies.
The Cambridge, UK-based gene synthesis firm plans to use the funds to accelerate development of its silicon platform and introduce a desktop device.
La Jolla, California-based DermTech has agreed to sell common and preferred stock to a number of undisclosed institutional investors.
The financing follows InformedDNA's signing of definitive agreements to receive growth capital investments with a number of investment groups.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.